Acute oral toxicity of toltrazuril in rats

The present study was conducted to assess acute oral toxicity of Toltrazuril in rats. The rats (Wistar, 2 to 2.5 months) were divided into five groups of six rats in each as Control, Test Group I (Toltrazuril @ 12.5 mg/kg, po), Test Group II (25 mg/kg po), Test Group III (50 mg/kg po) and Test Group IV (100 mg/kg po). At the end of the study, no significant changes were found in Hb, PCV, TEC and TLC of test groups I, II, and III as compared to control group. However, there were significant (P<0.01) decrease in Hb (11.47±0.18) and PCV (35.63±0.77) values of rats of group IV as compared to control group. Rats of test group IV showed significant (P<0.01) increase in AST (76.35±1.40) and ALT (28.56±0.43) values as compared to control group. The data obtained from the acute oral toxicity study of Toltrazuril in rats indicates that Coxuril® (Toltrazuril 2.5% oral solution) is safe for clinical use at therapeutic dose (7 mg.kg^-1 b.wt.).